Biomaterial Database

Development and production aspects of a recombinant yeast-derived hepatitis B vaccine. 1990

J Stephenne

SmithKline Biologicals, Rixensart, Belgium.

Any attempt to control or eradicate hepatitis B on a global scale requires the availability of large quantities of effective, safe and affordable hepatitis B vaccine. The drawbacks of the first generation of plasma-derived vaccines--poor acceptance, relatively high cost, limited availability--have led to the search for alternative means of producing hepatitis B vaccines. This article reviews the development and production of a yeast-derived vaccine based on recombinant DNA technology and discusses potency, stability and potential availability for use in the implementation of vaccination programmes.

UI	MeSH Term	Description	Entries
D006801	Humans	Members of the species Homo sapiens.	Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D012441	Saccharomyces cerevisiae	A species of the genus SACCHAROMYCES, family Saccharomycetaceae, order Saccharomycetales, known as "baker's" or "brewer's" yeast. The dried form is used as a dietary supplement.	Baker's Yeast,Brewer's Yeast,Candida robusta,S. cerevisiae,Saccharomyces capensis,Saccharomyces italicus,Saccharomyces oviformis,Saccharomyces uvarum var. melibiosus,Yeast, Baker's,Yeast, Brewer's,Baker Yeast,S cerevisiae,Baker's Yeasts,Yeast, Baker
D014614	Vaccines, Synthetic	Small synthetic peptides that mimic surface antigens of pathogens and are immunogenic, or vaccines manufactured with the aid of recombinant DNA techniques. The latter vaccines may also be whole viruses whose nucleic acids have been modified.	Antigens, Synthetic,Chemical Vaccine,Chemical Vaccines,Immunogens, Synthetic,Molecular Vaccine,Molecular Vaccines,Recombinant Vaccine,Semisynthetic Vaccine,Semisynthetic Vaccines,Synthetic Antigen,Synthetic Vaccine,Synthetic Vaccines,Vaccines, Recombinant,Synthetic Antigens,Synthetic Immunogens,Vaccines, Chemical,Vaccines, Molecular,Vaccines, Semisynthetic,Antigen, Synthetic,Recombinant Vaccines,Vaccine, Chemical,Vaccine, Molecular,Vaccine, Recombinant,Vaccine, Semisynthetic,Vaccine, Synthetic
D014761	Viral Hepatitis Vaccines	Any vaccine raised against any virus or viral derivative that causes hepatitis.	Hepatitis, Viral, Vaccines,Hepatitis Vaccines, Viral,Vaccines, Viral Hepatitis
D017325	Hepatitis B Vaccines	Vaccines or candidate vaccines containing inactivated hepatitis B or some of its component antigens and designed to prevent hepatitis B. Some vaccines may be recombinantly produced.	Hepatitis B Vaccine,Vaccine, Hepatitis B,Vaccines, Hepatitis B

Related Publications

J Stephenne

Recombinant yeast hepatitis B vaccine.

January 1986, Developments in biological standardization,

J Stephenne

Yeast recombinant hepatitis B vaccine.

January 1987, Infection,

J Stephenne

Results of immunisation with a recombinant yeast-derived hepatitis B vaccine.

July 1986, The Journal of infection,

J Stephenne

Reactogenicity and immunogenicity of a new recombinant yeast-derived hepatitis B vaccine.

November 1988, Zentralblatt fur Bakteriologie, Mikrobiologie, und Hygiene. Series A, Medical microbiology, infectious diseases, virology, parasitology,

J Stephenne

Immunogenicity of a recombinant yeast-derived hepatitis B vaccine (Engerix B) in children.

April 1988, The New Zealand medical journal,

J Stephenne

Effects of a recombinant yeast-derived hepatitis B vaccine in healthy adults.

January 1987, Postgraduate medical journal,

J Stephenne

[Immunogenicity and safety of recombinant yeast-derived hepatitis B vaccine in adults].

November 2002, Zhonghua yu fang yi xue za zhi [Chinese journal of preventive medicine],

J Stephenne

Yeast-derived hepatitis B vaccine and yeast sensitivity.

April 1989, Lancet (London, England),